Drug Trial Radar · NCT00468923
Heart Outcomes Prevention Evaluation-3
Last checked: Nov 20, 2026Latest source record: Oct 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12,705
Actual
Start
May 2007
Primary completion
Dec 2015
Study completion Jan 2016
Sponsor
- Lead sponsor
- Population Health Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 3, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Heart disease and stroke are major causes of death and disability worldwide and are largely preventable. Cholesterol and blood pressure are major cardiovascular risk factors. Previous studies have shown that certain drugs can effectively and safely lower cholesterol and blood pressure and prevent heart attacks and strokes. Such studies have been conducted primarily in people who had already sustained a heart attack or a stroke, or in people with high cholesterol and blood pressure levels. However, most heart attacks and strokes occur in people with average ("normal") cholesterol and blood pressure. Therefore, in the HOPE-3 trial the investigators will evaluate whether a cholesterol lowering drug, rosuvastatin, and a combination blood pressure lowering pill, candesartan/hydrochlorothiazide, used alone or together can reduce the risk of heart attacks, stroke and their sequelae in people without known heart disease and at average risk.
Conditions
- Cardiovascular Disease
- Stroke
Interventions
Candesartan/HCTDrug
Candesartan 16 mg/HCT 12.5 once daily
RosuvastatinDrug
Rosuvastatin 10 mg once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- The composite of; Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke.Time frame: Biannually
- The composite of; cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, heart failure, arterial revascularizationsTime frame: Biannually
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hamilton General Hospital
Hamilton, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.